HDAC6型
效应器
肿瘤微环境
免疫系统
癌症研究
免疫检查点
黑色素瘤
封锁
免疫疗法
表型
细胞毒性
免疫学
化学
表型筛选
生物
细胞周期检查点
T细胞
抗原
药品
巨噬细胞
肿瘤浸润淋巴细胞
化学免疫疗法
免疫
免疫耐受
作者
Nithya Gajendran,Manasa Suresh,Sebastian Marquez R.,Sruthi Mohan,Tim Ponsot,David Quiceno-Torres,Mario A. Noboa,Bryan T. Weselman,Xintang Li,Marie Durr,Zora Nováková,Mike Schutkowski,Matías I. Hepp,Satish Kumar Reddy Noonepalle,Cyril Bařinka,Duncan J. Wardrop,Alejandro Villagra
标识
DOI:10.1021/acs.jmedchem.5c02453
摘要
Tumor-associated macrophages (TAMs) play a pivotal role in shaping the tumor microenvironment (TME) and influencing the outcomes of immunotherapy. However, most drug screening strategies emphasize tumor cell cytotoxicity and neglect immune effector modulation. Here, we describe a macrophage-centric phenotypic screening platform to identify selective HDAC6 inhibitors that reprogram TAMs toward an antitumor phenotype. Building on the HDAC6 inhibitor SS-208, we synthesized a novel class of tetrazolone-based compounds with potent selectivity and minimal cytotoxicity. Among these, SM-06-09 emerged as a lead candidate, showing subnanomolar HDAC6 inhibition, enhanced macrophage phagocytosis, antigen presentation, and T-cell activation in vitro. In a syngeneic melanoma model, SM-06-09 suppressed tumor growth and promoted M1-like TAM polarization. Combination with anti-PD-1 therapy further enhanced immune infiltration, increased effector memory and central memory T-cells, and improved antitumor efficacy. This study establishes a functional screening framework for identifying immunomodulatory compounds and supports the clinical potential of macrophage-targeted HDAC6 inhibitors as adjuncts to immune checkpoint blockade.
科研通智能强力驱动
Strongly Powered by AbleSci AI